Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBViNT Cell in EBV-Positive Malignancies
NCT03789617Phase 2Unknown
- Sponsor
- Eutilex Co., Ltd.
- Start
- Dec 2018
- Primary completion
- Sep 2022
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of EBViNT cell in Extranodal NK/T-cell lymphoma (ENKTL), gastric cancer (GC), esophageal adenocarcinoma (EAC), sponsored by Eutilex Co., Ltd.. Status: unknown.
02
Drugs
EBViNT cell
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)gastric cancer (GC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT03789617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03789617.